Where can I buy shares of nrix?
Shares of NRIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
What is the dividend policy for National Research Corporation (NRC)?
Lincoln, Nebraska, Feb. 14, 2022 (GLOBE NEWSWIRE) -- National Research Corporation, dba NRC Health, (NASDAQ:NRC) announced that its Board of Directors has declared a quarterly cash dividend of $0. 24 (twenty-four cents) per share payable Friday, April 15, 2022, to shareholders of record as of the close of business on Thursday, March 31, 2022.
How much of nurix Therapeutics'stock is owned by insiders?
In the past three months, Nurix Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $134,828.00 in company stock. Only 6.30% of the stock of Nurix Therapeutics is held by insiders. 90.57% of the stock of Nurix Therapeutics is held by institutions.
What does NRC stand for?
For more than 40 years, National Research Corporation has been a leading provider of analytics and insights that facilitate measurement and improvement of H LINCOLN, Neb., Feb. 08, 2022 (GLOBE NEWSWIRE) -- National Research Corporation (NASDAQ:NRC) today announced results for the fourth quarter of 2021.
What is NRIX 2021?
SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s chief executive officer, will participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14th, 2021 at 11:45 a.m. ET. The event will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. An archived copy of the webcast will be available on the Nurix website for approximately 30 days after the event. About Nurix Therapeutics, Inc. Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For more information, please visit http://www.nurix.com. Contacts: Investors:Media:Jason Kantor, Ph.D.Elizabeth Wolffe, Ph.D.Nurix Therapeutics, Inc.Wheelhouse Life Science [email protected]@wheelhouselsa.com
When did Nurix get FDA approval?
Nurix filed an IND for NX-2127 in December 2020 and received clearance by the U.S. FDA to initiate human clinical trials. Clinical sites are actively recruiting patients for a Phase 1 clinical trial of NX-2127.
What is Nurix Therapeutics?
Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases.
How much is the net loss for 2021?
Net loss attributed to common stockholders for the three months ended February 28, 2021 was $24.3 million, or ($0.63) per share, compared to a net loss of $12.4 million, or ($3.50) per share, for the three months ended February 29, 2020.
When will Nurix Therapeutics release its earnings?
Nurix Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, October 12th 2021. View our earnings forecast for Nurix Therapeutics.
How much does Nurix Therapeutics make?
Nurix Therapeutics has a market capitalization of $1.36 billion and generates $17.82 million in revenue each year. The company earns $-43,240,000.00 in net income (profit) each year or ($2.76) on an earnings per share basis.
What is NRC Health?
About NRC Health For more than 40 years, National Research Corporation (NRC Health) (NASDAQ: NRC) has been committed to achieving Human Understanding and bringing healthcare organizations closer to their customers than ever before by illuminating and improving the key moments that define an experience and build trust.
What is the net income for the first quarter of 2021?
Net income for first quarter 2021 was $9.2 million, compared to $11.8 million for the same period last year. Diluted earnings per share decreased to $0.36 for the quarter ended March 31, 2021, from diluted earnings per share of $0.46 for the quarter ended March 31, 2020.
What is NCR 2021?
ATLANTA, Jun 22, 2021--NCR Corporation (NYSE: NCR), a global enterprise technology provider for the financial industry, and the ATM Industry Association (ATMIA), today announced certification of NCR’s Activate Enterprise NextGen ATM application to Level 2 of the new ATMIA Next Gen Framework.
When will NCR close?
ATLANTA, Jun 15, 2021--NCR Corporation (NYSE: NCR), a global enterprise technology provider for the financial, retail and hospitality industries, today announced that it remains on track to close the legal transaction with Cardtronics (Nasdaq: CATM) and expects to complete the transaction on June 21, 2021.
Is NCR closing in 2021?
ATLANTA, Jun 15, 2021--NCR Corporation (NYSE: NCR), a global enterprise technology provider for the financial, retail and hospitality industries, today announced that it remains on track to close the legal transaction with Cardtronics (Nasdaq: CATM) and expects to complete the transaction on June 21, 2021.